Lucio Gordan
YOU?
Author Swipe
View article: The Role Of Utilizing Community Oncology Care To Decrease Cancer-Related Financial Toxicity.
The Role Of Utilizing Community Oncology Care To Decrease Cancer-Related Financial Toxicity. Open
The cost of cancer care in the United States remains a significant concern, particularly considering the rising expenditures associated with oncology services1. Cancer related financial toxicity - the economic burden of cancer care to pati…
View article: Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review
Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review Open
In this real-world evaluation of ESA treatment in a population with LR-MDS, only one-third of patients experienced hematologic improvement and two-thirds of patients remained on ESA treatment for ≥1 year after failure. These results demons…
View article: Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma
Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma Open
There are opportunities to reduce the barriers for the use of MRD testing and for generation of additional data on the clinical impact of these test results to support the development of guidelines and provide further education on the impl…
View article: Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States Open
Teclistamab was associated with significantly lower treatment costs and numerically lower cost per responder than elranatamab in triple class-exposed RRMM.
View article: Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis
Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis Open
Daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are guideline‐recommended preferred regimens for initial treatment of transplant‐ineligible (TIE) …
View article: Development of anti-cancer medicines in the current era
Development of anti-cancer medicines in the current era Open
The successful development of anticancer medicines is arduous and highly technical. Although clear to some, many sponsors are not aware of regulatory mandates and processes leading to delays and missed opportunities. Drug development begin…
View article: Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor
Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor Open
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use of supportive care and patient education. We investigated the impact of a BP program …
View article: Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study Open
DRd is associated with a significantly lower risk of disease progression or death compared to VRd as 1L treatment for TIE NDMM patients.
View article: POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)
POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS) Open
View article: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study
MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study Open
View article: POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study
POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study Open
View article: Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data
Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data Open
PURPOSE Identification and targeting of actionable oncogenic drivers (AODs) in advanced non–small-cell lung cancer (NSCLC) has dramatically improved outcomes. However, genomic testing uptake is variable and hampered by factors including sl…
View article: Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy
Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy Open
The existing evidence suggests that trilaciclib may reduce single and multilineage grade ≥ 3 myelosuppressive HAEs and cytopenia-related healthcare utilization among patients with ES-SCLC in the real world. It is a promising new treatment …
View article: Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices
Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices Open
Background Myelosuppression is a major dose‐limiting complication of chemotherapy for patients with extensive‐stage small cell lung cancer (ES‐SCLC). The objective was to describe the burden of myelosuppression, treatment patterns, and sup…
View article: Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer Treated with Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer Treated with Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices Open
View article: 1162P Tissue and liquid biopsy utilization in advanced NSCLC in a large community US practice
1162P Tissue and liquid biopsy utilization in advanced NSCLC in a large community US practice Open
View article: Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial Open
Objectives The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine wheth…
View article: Defining appropriate quality performance metrics for pharmacies dispensing oral oncology therapies
Defining appropriate quality performance metrics for pharmacies dispensing oral oncology therapies Open
Pharmacy benefit managers use measures like the medication possession ratio (MPR) as a performance/quality metric to evaluate specialty pharmacies and assess direct and indirect remuneration clawback fees. Abundant evidence shows that meas…
View article: Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial Open
Background CheckMate 920 ( NCT02982954 ) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clin…
View article: Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920 Open
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long‐term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain…
View article: Daratumumab Utilization and Cost Analysis among Patients with Multiple Myeloma in a US Community Oncology Setting
Daratumumab Utilization and Cost Analysis among Patients with Multiple Myeloma in a US Community Oncology Setting Open
Background: The introduction of daratumumab into the treatment of multiple myeloma has improved outcomes in patients; however, community oncologists often dose more frequently than the US FDA-approved label. Materials and methods…
View article: Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study
Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study Open
This study provides real-world evidence on the practice patterns of daratumumab rapid infusions in a large community-based oncology clinic system. These results suggest that treatment regimens including daratumumab rapid infusions at the t…
View article: Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors
Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors Open
PURPOSE While the immediate care and access disruptions associated with the COVID-19 pandemic have received growing attention in certain areas, the full range of gaps in cancer screenings and treatment is not yet well understood or well do…
View article: Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data Open
Leuprolide acetate therapies were frequently administered late. Gel formulation demonstrated higher rates of testosterone 50 ng/dl or less and 20 ng/dl or less than microsphere formulation. Optimal testosterone suppression can impact prost…
View article: Augmentation of Cancer Cachexia Components With Targeted Acupuncture in Patients With Gastrointestinal Cancers: A Randomized Controlled Pilot Study
Augmentation of Cancer Cachexia Components With Targeted Acupuncture in Patients With Gastrointestinal Cancers: A Randomized Controlled Pilot Study Open
Introduction: Patients with gastrointestinal (GI) cancer-associated cachexia are at risk of high morbidity and mortality. This randomized single-blind pilot study compared the complementary use of targeted acupuncture (TA) with nontargeted…
View article: Cost Differences Associated With Oncology Care Delivered in a Community Setting Versus a Hospital Setting: A Matched-Claims Analysis of Patients With Breast, Colorectal, and Lung Cancers
Cost Differences Associated With Oncology Care Delivered in a Community Setting Versus a Hospital Setting: A Matched-Claims Analysis of Patients With Breast, Colorectal, and Lung Cancers Open
Purpose: Access to high-quality cancer care remains a challenge for many patients. One such barrier is the increasing cost of treatment. With recent shifts in cancer care delivery from community-based to hospital-based clinics, we examined…
View article: Body composition changes differ by gender in stomach, colorectal, and biliary cancer patients with cachexia: Results from a pilot study
Body composition changes differ by gender in stomach, colorectal, and biliary cancer patients with cachexia: Results from a pilot study Open
Few studies have examined the possibility that cachexia may affect men and women differently. This pilot study assessed gender differences in body composition in stomach, colorectal, and biliary cancer patients with cachexia. A sample of 3…
View article: Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?
Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed? Open
Purpose: Medicare currently enrolls ≥ 45 million adults, and by 2030 this is projected to increase to ≥ 80 million beneficiaries. With this growth, the Centers for Medicare & Medicaid Services (CMS) issued a proposal, the Medicare Part B D…